BAL Lazio


HTA – Bibliografia 2004-2000

Pubblicato lunedì 5 Maggio 2014

I volumi e gli articoli citati sono in ordine cronologico, in modo da mettere in evidenza quelli più recenti, in cima all’elenco.

Clausen C, Yoshinaka Y. Social shaping of technology in TA and Hta. Poiesis Prax 2004; 2 (2,3): 221-46.

ten Have H. Ethical perspectives on health. Int J Technol Assess Health Care 2004; 20 (1): 1-76.

The GRADE working group. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches. BMC Health Serv Res 2004; 4 (1): 38.

Hailey D, Kristensen FB. The current status of the INAHTA project. Impact of HTA in Policy and Practice–The experiences of the INHTA Agencies. HTAi 2004; Pre-conference.

Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36).

Alberta Heritage Foundation for Medical Research. A study of the impact of 2001-2002 health technology assessment products-final report. IP-15 Information Paper 2003; 34.

Banta D. The development of health technology assessment. Health Policy 2003; 63: 121-32.

Cicchetti A. Strategic planning in healthcare organizations: the role of health technology assessment. In: Geisler E, Krabbendam K, Schuring R, eds. Technology, healthcare and management in the hospital of the future. Westport, London: Praeger, 2003: 67-80.

Del Vecchio M, Cosmi L. Il risk management nelle aziende sanitarie. Milano: McGraw-Hill, 2003.

Leys M. Health technology assessment: the contribution of qualitative research. Int J Technol Assess Health Care 2003; 19 (2): 317-29.

Narath MA. Das Gespenst der Rationierung in reichen Ländern, Sozialmedizinisches Zentrum Liebenau, Graz, 2002.

Kristensen FB, Horder M, Poulsen PB, eds. Health technology assessment handbook. Danish Institute for Health Technology Assessment (DIHTA) 2001.

Moher D, Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trial. Lancet 2001; 357: 1191-4.

Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. Metodi per la valutazione economica dei programmi sanitari. Seconda edizione. Edizione italiana a cura di Fattore G, Garattini L, Lucioni C. Roma: Il Pensiero Scientifico Editore, 2000.

Lehoux P, Blume S. Technology assessment and the sociopolitics of health technologies. J Health Polit Policy Law 2000; 25 (6): 1083-118.

Tagged ,

Lascia un commento

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *

Accedi agli articoli

Garutti M et al. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open 2021;6(5):100276.

Hauptman M et al. Individual- and community-level factors associated with detectable and elevated blood lead levels in US children: results from a national clinical laboratory. JAMA Pediatr. Published online September 27, 2021. doi:10.1001/jamapediatrics.2021.3518

Marcus GM et al. Acute consumption of alcohol and discrete atrial fibrillation events. Ann Intern Med 2021 Aug 31. doi: 10.7326/M21-0228. Epub ahead of print. PMID: 34461028.

Fakir AMS et al. Pandemic catch-22: the role of mobility restrictions and institutional inequalities in halting the spread of COVID-19. PLOS ONE 2021; 16(6): e0253348.

Alemany S, Avella-García C, Liew Z, et al. Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts. Eur J Epidemiol (2021).

Salazar de Pablo G et al. Universal and selective interventions to prevent poor mental health outcomes in young people: systematic review and meta-analysis. Harvard Review of Psychiatry 2021;29 (3) 196-215.

Currie JM et al. Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the covid-19 pandemic. JAMA Netw Open 2021;4(4):e216147.

Marson A, Burnside G, Appleton R, et al.; SANAD II collaborators. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021;397(10282):1375-1386.

Marson A, Burnside G, Appleton R, et al.; SANAD II collaborators. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet 2021;397(10282):1363-1374.

Una finestra sull’open access

  • BMC Family Practice
  • BMC Medical Education
  • BMC Nursing
  • BMJ Open
  • PLOS Medicine

Reset della password

Per favore inserisci la tua email. Riceverai una nuova password via email.